期刊文献+

大剂量甲氨蝶呤血药浓度监测与影响因素分析 被引量:9

Serum Concentration in High-dose Methotrexate Treatment and Related Factors
暂未订购
导出
摘要 目的研究采用大剂量甲氨蝶呤(MTX)化疗的急性淋巴细胞白血病(ALL)患者MTX血药浓度的影响因素。方法采用高效液相色谱法测定MTX给药后24h、48h、72h血药浓度,实时荧光定量PCR法分析ABCC2 4240C>T和4568A>C基因型,多重线性回归逐步筛选变量法分析血药浓度与年龄、基因型等因素的关系。结果 MTX给药剂量、基因型(ABCC2 4240C>T和4568A>C)能够影响MTX 48h和72h血药浓度,MTX用药次数与MTX的48h浓度成正比。结论 MTX血药浓度监测与ABCC2 4240C>T和4568A>C基因型检测对MTX的个体化用药具有指导意义。 Objective To investigate the factors influencing the methotexate(MTX) concentration in acute lymphoblasdc leukemia patients. Methods The serum concentration of MTX at 24h, 48h and 72h was determined by HPLC. The genotype of ABCC2 4240C 〉T and 4568A〉C was analyzed by real-time qPCR. Multi-linear regression with stepwise was conducted to select the factors that affected MTX concentration. Results MTX dose, ABCC2 4240C〉T and 4568A〉C were able to affect the MTX concentration at 48h and 72h. MTX treatment duration was related to the increased MTX concentration at 481-L Conclusion Clinical monitoring of MTX concentration as well as detecting ABCC2 4240C〉T and 4568A〉C genotype could reduce the occurrence of adverse reaction.
出处 《中国药物警戒》 2013年第10期577-579,582,共4页 Chinese Journal of Pharmacovigilance
关键词 甲氨蝶呤 血药浓度 影响因素 methotrexate serum concentration influencial factors
  • 相关文献

参考文献8

  • 1Csordas IC Hegyi M, Eipel O T, et al. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia[J]. Anticancer Drugs, 2013, 24(2): 189-197.
  • 2Klapkova E, Kukacka J, Kotaska K, et al. The influence of 7-OH methotrexate metabolite on clinical relevance of methotrexate determination[J]. Clin Lab, 2011, 57 ( 7-8 ): 599-606.
  • 3de Beanmais T A, Jacqz-Aigrain E. Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children [J]. Curr Drug Metab, 2012, 13(6): 822-834.
  • 4Vlaming M L, van Esch A, Pala Z, et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrpl) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo[J]. Mol Cancer Tber, 2009, 8( 12 ): 3350-3359.
  • 5Rubs H, Becker A, Drescher A, et al. Population PK/PD model of homocysteine concentrations "alter high-dose methotrexate treatment in patients with acute lymphoblastic leukemia[J]. PLoS One, 2012, 7(9 ): e46015.
  • 6E1-Khodary N M, EI-Haggar S M, Eid M A, et al. Study of the pharmacokinelic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia[J]. Med Oncol, 2012, 29( 3 ): 2053-2062.
  • 7Ho W F, Koo S H, Yee J Y, et al. Genetic variations of the ABCC2 gene in the Chinese, Malay, and Indian populations of Singapore[J]. Drug Metab Pharmacokinet, 2008, 23( 5 ): 385-391.
  • 8Wang Y M, Sutow W W, Romsdahl M M, et al. Age-related phar- macokinetics of high-dose methotrexate in patients with osteosa- rcoma[J]. Cancer Treat Rep, 1979, 63 ( 3 ): 405-410.

同被引文献116

引证文献9

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部